ResMed Acquires Noctrix Health for $340M

In a significant move within the connected health sector, ResMed has finalized the acquisition of Noctrix Health for a substantial $340 million. This strategic integration promises to enhance ResMed's existing sleep health and respiratory care offerings by incorporating Noctrix Health's innovative neuromodulation therapies. The deal marks a pivotal moment for Angelini Ventures, representing its inaugural portfolio company exit and underscoring its investment thesis in pioneering healthcare technologies that address critical unmet patient needs.

Noctrix Health, established in 2016, has carved a niche in developing wearable, clinically validated treatments for chronic neurological and sleep disorders. Its flagship product, Nidra, stands out as the first non-invasive therapy authorized by the FDA for moderate-to-severe Restless Legs Syndrome (RLS). This condition affects millions globally, and Nidra offers a novel therapeutic avenue, positioning Noctrix Health as a key innovator in its field. The acquisition by ResMed, a recognized global leader, is expected to significantly broaden the reach and impact of this groundbreaking therapy.

Angelini Ventures, the corporate venture arm of Angelini Industries, strategically invested in Noctrix Health during its 2024 Series C funding round, contributing to the company's $40 million raise. This investment was part of Angelini Ventures' broader commitment to backing differentiated healthcare solutions with the potential for scalable adoption. The successful exit validates the firm's approach of combining capital with deep industry expertise and a robust network to foster growth in promising healthtech ventures.

“This acquisition is a testament to our strategy of identifying and nurturing disruptive healthcare companies that possess the potential to make a profound difference in patient lives,” stated Paolo Di Giorgio, CEO and Managing Director of Angelini Ventures. “Noctrix Health perfectly embodies our investment criteria, showcasing advanced scientific innovation and clear clinical utility. We are enthusiastic about its integration into ResMed’s extensive connected health platform, which will undoubtedly expand patient access and enhance care delivery on a global scale.”

The medical technology market, particularly in sleep and neurological disorders, is experiencing robust growth, driven by an aging population and increasing awareness of chronic conditions. The global market for sleep aids is projected to reach tens of billions of dollars in the coming years, with neuromodulation technologies representing a rapidly expanding segment. ResMed's move to acquire Noctrix Health aligns with this trend, signaling a strong focus on expanding its therapeutic portfolio beyond traditional CPAP devices into more advanced treatment modalities.

Tanja Dowe, Managing Director at Angelini Ventures and former Board Observer for Noctrix Health, highlighted the exceptional execution by the Noctrix team. “It was a privilege to support Noctrix Health through a critical growth phase. Their swift progress in clinical development, regulatory approvals, and commercialization has been remarkable. We are proud to have been part of bringing a first-in-class therapy for RLS patients to fruition.” This sentiment was echoed by Sergio Marullo di Condojanni, CEO of Angelini Industries, who emphasized the group's dedication to fostering innovations that yield tangible benefits for patients and healthcare systems worldwide.